Does Flolan Cause Withdrawal Symptoms?
Yes, abrupt discontinuation of Flolan (epoprostenol), a continuous IV infusion for pulmonary arterial hypertension (PAH), can trigger severe withdrawal symptoms due to rebound pulmonary hypertension. These occur because the drug maintains low pulmonary vascular resistance; stopping it suddenly causes rapid deterioration.[1][2]
What Are the Specific Withdrawal Symptoms?
Patients experience acute worsening of PAH symptoms within minutes to hours, including:
- Dyspnea (shortness of breath)
- Dizziness or syncope
- Chest pain
- Tachycardia (rapid heart rate)
- Hypoxia (low blood oxygen)
- In severe cases, right heart failure, cardiogenic shock, or death.
These effects stem from a rebound increase in pulmonary artery pressure, often exceeding pre-treatment levels.[1][3]
Why Does Withdrawal Happen So Quickly?
Flolan has a short half-life of about 6 minutes, requiring uninterrupted infusion. Any pump failure, line occlusion, or sudden stop leads to immediate loss of effect, unlike oral PAH drugs with longer durations.[2][4]
How to Safely Discontinue Flolan
Never stop abruptly. Transition requires:
- Hospital monitoring
- Weaning via dose reduction or bridging to IV treprostinil (Remodulin), which has a longer half-life
- Backup infusion systems to prevent interruptions
Guidelines from the American College of Chest Physicians emphasize gradual tapering over days to weeks.[1][5]
What Do Patients Report in Real Cases?
Case reports document fatalities from accidental disconnections lasting under 30 minutes. Survivors often need mechanical ventilation or vasopressors. Patient forums highlight anxiety over pump reliability.[3][6]
Alternatives to Avoid Withdrawal Risks
Switching to subcutaneous or inhaled prostacyclins (e.g., Remodulin, Tyvaso) reduces IV dependency but still requires careful management. Oral options like sildenafil or riociguat have no infusion risks but differ in efficacy.[4][7]
[1]: FDA Flolan Label
[2]: UpToDate: Epoprostenol Management
[3]: Chest Journal Case Report (2002)
[4]: ESC/ERS PAH Guidelines (2015)
[5]: ACCP Consensus (2009)
[6]: Pulmonary Hypertension Association Patient Stories
[7]: DrugPatentWatch: Flolan vs. Alternatives